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Abstract. The aim of the present study was to investigate 
whether genetic markers considered risk factors for metabolic 
syndromes, including dyslipidemia, obesity and type 2 diabetes 
mellitus (T2DM), can be applied to a Northeastern Mexican 
population. A total of 37 families were analyzed for 63 single 
nucleotide polymorphisms (SNPs), and the age, body mass index 
(BMI), glucose tolerance values and blood lipid levels, including 
those of cholesterol, low-density lipoprotein (LDL), very LDL 
(VLDL), high-density lipoprotein (HDL) and triglycerides were 
evaluated. Three genetic markers previously associated with 
metabolic syndromes were identified in the sample popula-
tion, including KCNJ11, TCF7L2 and HNF4A. The KCNJ11 
SNP rs5210 was associated with T2DM, the TCF7L2 SNP 
rs11196175 was associated with BMI and cholesterol and LDL 
levels, the TCF7L2 SNP rs12255372 was associated with BMI 
and HDL, VLDL and triglyceride levels, and the HNF4A SNP 
rs1885088 was associated with LDL levels (P<0.05).
Introduction
Previous studies employing family-based association tests 
(FBAT) have identified numerous genes that may have a role 
in diabetes and obesity (1-3). In addition, more than 330 genes, 
161 candidate regions and 103,077 single nucleotide poly-
morphisms (SNPs) have been associated with type 2 diabetes 
mellitus (T2DM) in European, African-American, Asian and 
Latino population (4). However, only ~40 candidate genes 
have been validated (5).
Detailed studies of population structure with geographical 
data are required to assess the frequency and the prevalence of 
genetic diseases in populations of European and Amerindian 
descent as these are genetically diverse; these and Mexican 
native populations are ethnically diverse across Mexico (6). The 
ancestry informative markers (AIMs) may be applied to deter-
minate the population structure in the European/Amerindian 
populations in association studies (7). The use of AIMs in 
population structure studies reduce population heterogeneity in 
complex populations, and may reduce the genetic heterogeneity 
for specific traits, false positives in multifactorial diseases and 
multifactorial traits. Sixty four AIMs are sufficient to deter-
mine the genetic contribution of Amerindian contribution in 
Mexican American populations (using r2>0.8 as the threshold 
to define a high correlation) (7). 
The present study aimed to determine whether 63 SNPs, 
including 37 genes and four intergenic regions, that have previ-
ously been associated with T2DM, body mass index (BMI) 
and dyslipidemia (5), could be identified in the Northeastern 
Mexican population.
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Materials and methods
Study design. A total of 37 families (178 individuals) 
were enrolled in the present study between June 2010 and 
June 2011. The present study was approved by the Committee 
for Ethics, Research and Biosecurity at the School of Nursing 
(Autonomous University of Nuevo León, Monterrey, Mexico; 
registry no. FAEN-0-449). In order for a family to be included 
in the present study, at least one parent had to have been diag-
nosed with T2DM. Conversely, a family was excluded from 
the present study if a parent had been diagnosed with type 1 
diabetes. Written informed consent was obtained.
Anthropometric and biochemical parameters. Body composi-
tion was assessed by air impedance plethysmography (Bod 
Pod Gold Standard; Cosmed, Concord, CA, USA). The BMI 
was calculated according to World Health Organization guide-
lines (8). In order to assess biochemical parameters, 30-ml 
venous blood samples were collected following a 12-14 h 
fasting period. The blood glucose level was determined using 
the glucose oxidase method, and the total levels of cholesterol 
(mg/dl), high-density lipoprotein (HDL; mg/dl), low-density 
lipoprotein (LDL; mg/dl), very LDL (VLDL; mg/dl), glycated 
hemoglobin (HbA1c; mg/dl) and triglycerides (mg/dl) in serum 
or plasma, depending on the kit used, were examined. HbA1c 
and oral glucose tolerance (OGTT) standardized fasting was 
performed in all undiagnosed parents. T2DM was confirmed 
using the American Diabetes Association criteria (9), as 
follows: i) A 2-h oral glucose tolerance test (OGTT120) glucose 
level ≥200 mg/dl (≥11.1 mmol/l); and/or ii) HbA1c ≥6.5%.
Nucleic acid extraction. DNA was extracted from 200 µl 
ethylenediaminetetraacetic acid-treated whole blood samples, 
using the QIAamp® DNA Blood Mini kit and the automated 
QIAcube system (cat nos. 51106 and 9001292; Qiagen GmbH, 
Hilden, Germany). Purified DNA was collected at a final 
volume of 150 µl and stored at ‑20˚C prior to analysis.
SNP selection. A total of 63 SNPs that have previously been 
associated with T2DM in other populations, and 61 ancestry 
informative markers (AIMs) (10) were genotyped. The 
63 SNPs associated with T2DM were present in the following 
genes: ADAMTS9, CAPN10, CD36, CDKAL1, ENPP1, 
EPHX2, FABP2, FTO, HHEX, HNF1B, HNF4A, IGF2BP2, 
JAZF1, KCNJ11, KCNQ1, LEPR, MAPK1, MAPK14, MTHFR, 
NEUROD1, SCAF4, NOTCH2, PCK1, PON1, PPARG, RCAN1, 
RPTOR, SLC2A2, SLC30A8, TCF7L2, THADA, TNF, UCP3, 
USF1, VLDR, WNT5B and WSF1. In addition, certain SNPs 
were present in the CDKN2A-CDKN2B, CDC123-CAMK1D, 
FAT3-MTNR1B and TSPAN8-LGR5 intergenic regions.
Genotype analyses. Molecular analyses were performed 
using TaqMan® Assays (Applied Biosystems; Thermo Fisher 
Scientific, Inc., Waltham, MA, USA), and analyzed using an 
OpenArray® NT Genotyping System (Applied Biosystems; 
Thermo Fisher Scientific, Inc.), according to the manufac-
turer's protocols. Briefly, DNA was diluted to a concentration 
of 50 ng/µl, mixed with Master mix (cat no. 4404846; Applied 
Biosystems; Thermo Fisher Scientific, Inc.) in a 384-well 
plate and transferred to the TaqMan OpenArray plate using 
an autoloader (250 copies/33 nl of the human haploid genome 
for each through-hole reaction). In addition, a non-template 
control (NTC) consisting of DNA-free and DNase-free 
double-distilled H2O was added to the plate. The plate was 
filled with immersion fluid, and sealed with glue. The multiplex 
TaqMan assay reactions were conducted in a Dual Flat Block 
GeneAmp PCR System 9700 (Applied Biosystems; Thermo 
Fisher Scientific, Inc.), under the following cycling conditions: 
Initiation at 93˚C for 10 min, followed by 50 cycles of 95˚C for 
45 sec, 94˚C for 13 sec and 53˚C for 14 sec. This was followed 
by termination at 25˚C for 2 min, and storage at 4˚C. The plate 
was designed to analyze 32 TaqMan assays for each sample. 
Allele analysis was performed using the TaqMan® Genotyper 
software, version 1.0 (Applied Biosystems, Thermo Fisher 
Scientific, Inc.) and using default parameters, according to the 
manufacturer's protocol. The accuracy of the genotyping was 
assessed by comparison with concordance calls generated for 
15 samples genotyped three times.
Statistical methods. Prior to conducting FBAT genetic anal-
yses, genotype statistics by marker and sample were performed. 
Families with only one parent, Mendelian errors (non-pater-
nity, non-maternity) and inbreeding were excluded, as were 
samples with a call rate (SNPs per sample/the total number 
of SNPs in the dataset) of <87%, and/or a Hardy-Weinberg 
equilibrium of P<0.01. FBAT was conducted using the PBAT 
package (http://www.hsph.harvard.edu/fbat/pbat.htm) with the 
FBAT-PC test statistic parameter in the SNP & Variation Suite 
(SVS) version 8 (goldenhelix.com/products/SNP_Variation/
index.html), which includes an FBAT extension (FBAT-PC) 
for longitudinal phenotypes, repeated measurements and 
correlated phenotypes (11). This method was applied to 
maximize the genetic component of the overall phenotypes 
and to minimize the phenotypic/environmental variance. The 
threshold for genome‑wide significance was set at P<4x10-4, 
which considers a significance level of 0.05 and 124 SNPs. The 
analyses were tested under additive, dominant, recessive and 
heterozygous advantage models, with a maximum pedigree 
size of 14, and no linkage or association as the null hypothesis. 
A probability-probability plot, linkage disequilibrium (LD) 
plots and box-and-whisker plots were generated using the SVS, 
version 8. A Composite Haplotype Method test (CHM) was 
applied to calculate the linkage disequilibrium, using SVS.
Results
Clinical and biochemical data. Among 173 patients (following 
5 exclusions), 94 (54.3%) were T2DM patients, 103 (59.5%) 
were women and 133 (77%) had a BMI ≥25 kg/m2. Regarding 
lipid levels, 113 subjects (65.3%) had LDL levels ≥100 mg/dl 
and 94 (54.3%) had triglyceride levels ≥150 mg/dl. For further 
clinical and biochemical data see Table I.
Genotype analyses. A total of 61 AIMs and 63 candidate SNPs 
that had been previously associated with T2DM in other popu-
lations were eligible for statistical analysis; acceptable quality 
control values and a minor allelic frequency of >0.01 was used, in 
accordance with previous studies (12). The SFRS15-rs2833483 
SNP was not in Hardy-Weinberg equilibrium (P<0.01) and thus 
was excluded from the present study.
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No significant inflation was detected between the observed 
and expected P-values (Fig. 1). The HNF4A-rs1885088 SNP 
was associated with LDL plasma level (P=2.8x10-4), with G 
as the risk allele in the dominant genetic model (Table II and 
Fig. 2). The rs5210 (Glu23Lys) variant of the KCNJ11 gene was 
associated with T2DM (P=9.6x10-5), with G as the risk allele 
(with OGTT120 as adjusted predictor variable) in the additive 
genetic model (Table II and Fig. 2). Two KCNJ11 SNPs were 
in LD when using the Composite Haplotype Method (CHM): 
rs5210 and rs5219 (r2=0.348697 and D'=1); rs5210 and rs5218 
(r2=0.461 and D'=1) (Fig. 3).
Among the five TCF7L2 SNPs analyzed, two (rs11196175 
and rs12255372) were associated with biochemical or clinical 
markers of metabolic syndrome (P<2.8x10-4). In particular, 
rs11196175 was associated with BMI and blood cholesterol 
Table I. Clinical and biochemical characteristics of subjects, reported as mean ± standard deviation.
 Females with Females without Males with Males without
Parameter T2DM T2DM T2DM T2DM
n (%) 58 (33.53%) 45 (26.01%) 36 (20.81%) 34 (19.65%)
Age (years)   46.53±17.13 (n=58)   43.64±16.43 (n=45)   53.92±16.71 (n=35)   47.29±20.25 (n=34)
OGTT120 (mg/dl) 175.70±90.35 (n=11) 132.68±34.26 (n=32) 208.85±87.05 (n=12) 125.13±37.70 (n=30)
HbA1c (%)   8.81±2.52 (n=58)   5.78±0.57 (n=43)   8.13±1.91 (n=36)   5.78±0.40 (n=34)
BMI (kg/m2) 29.93±5.27 (n=57) 29.92±5.52 (n=44) 27.56±4.18 (n=35) 28.53±6.04 (n=34)
Cholesterol (mg/dl) 211.30±48.24 (n=57) 193.52±42.01 (n=44) 196.36±45.13 (n=36) 191.15±47.98 (n=33)
TG (mg/dl)   212.52±146.59 (n=56) 161.98±77.56 (n=44)   279.56±235.88 (n=34)     185.8±118.60 (n=33)
LDL (mg/dl) 125.67±39.21 (n=55) 120.43±32.30 (n=44) 107.59±41.16 (n=32) 108.70±42.09 (n=33)
VLDL (mg/dl)   39.74±21.11 (n=55)   32.39±15.51 (n=44)   47.62±33.62 (n=32)   37.18±23.71 (n=33)
HDL (mg/dl)  43. 60±13.92 (n=55)   45.41±11.05 (n=44)   41.23±14.95 (n=32)   45.27±16.22 (n=33)
T2DM, type 2 diabetes mellitus; OGTT120, oral glucose tolerance test at 120 min; HbA1c, glycated hemoglobin; BMI, body mass index; 
TG, triglycerides; HDL, high-density lipoprotein; LDL, low-density lipoprotein; VLDL, very low-density lipoprotein.
 
Table II. Association between KCNJ11, HNF4A and TCFL2 variants and aspects of the metabolic syndrome.
Gene     SNP R/NR Allele Freqa HWb Freqc HWd Modele  Associated trait NIFf P-value
KCNJ11 rs5210 NR A 0.387 0.520 0.352 0.746 0 T2DM 23 4.0x10-4
KCNJ11 rs5210 R G 0.613 0.520 0.648 0.746 0 T2DM 23 9.6x10-5
HNF4A rs1885088 NR A 0.192 0.675 0.213 0.089 1 LDL 13 2.8x10-4
HNF4A rs1885088 R G 0.808 0.675 0.787 0.089 2 LDL 13 2.8x10-4
TCF7L2 rs11196175 NR C 0.090 0.816 0.098 0.394 1 BMI, cholesterol 10 1.3x10-4
TCF7L2 rs11196175 R T 0.910 0.816 0.902 0.394 2 BMI, cholesterol 10 1.3x10-4
TCF7L2 rs11196175 NR C 0.090 0.816 0.098 0.394 3 BMI, LDL 10 2.7x10-4
TCF7L2 rs11196175 R T 0.910 0.816 0.902 0.394 3 BMI, LDL 10 2.7x10-4
TCF7L2 rs12255372 NR G 0.890 0.216 0.877 0.274 0 BMI, TG, HDL, 14 1.9x10-3
         LDL, VLDL
TCF7L2 rs12255372 R T 0.110 0.216 0.123 0.274 0 BMI, TG, HDL, 14 2.2x10-4
         LDL, VLDL
aAllelic frequency of families. bHardy-Weinberg equilibrium of families. cAllelic frequency of parents. dHardy-Weinberg Equilibrium of parents; 
e0, additive; 1, Dominant; 2, Recessive; 3, Heterozygous advantage. fNumber of informative families. SNP, single nucleotide polymorphism; 
R/NR, risk/non-risk; T2DM, type 2 diabetes mellitus; LDL, low-density lipoprotein; BMI, body mass index; HDL, high-density lipoprotein; 
TG, triglycerides. 
 
Figure 1. Expected vs. observed P-values in a P-P plot.
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levels in the dominant and recessive genetic model, whereas 
it was associated with BMI and LDL in the heterozygous 
advantage genetic model. In both cases, the recessive T 
allele was associated with the increased risk (Table II and 
Fig. 2). Furthermore, rs12255372 was associated with BMI 
and HDL, LDL, VLDL and triglyceride levels in the addi-
tive genetic model, with the T allele posing the risk (Table II 
and Fig. 2). LD was detected for the following TCF7L2 
SNPs: rs7903146 and rs12255372 (CHM, r2=0.394019, D'= 
0.978698); rs11196175 and rs12255372 (CHM, r2=0.5720679, 
D'= 0.8342954); rs11196175 and rs7903146 (CHM, 
r2=0.2004928, D'=0.7584948) (Fig. 4).
Discussion
The present study demonstrated that the G allele in the HNF4A 
rs1885088 SNP was associated with a risk for increased circu-
lating LDL levels. Similarly, the HNF4A rs1800961 SNP has 
previously been associated with altered HDL levels (13). A 
previous study demonstrated that a reduction in the activity 
of the hepatocyte nuclear factors (HNFs)-4α and -1α led to an 
increased level of hepatic LDC receptors and, concordantly, 
lower levels of circulating LDL (14).
Numerous SNPs of the HNF4A gene have previously been 
associated with T2DM in various populations; the rs6017317 
SNP, which is located in the FITM2-R3HDML-HNF4A 
region, in East Asians (15), the rs1884613 SNP in Ashkenazian 
Jews (16), and the rs6031558, rs2071197 and rs3212183 SNPs, 
although not rs1885088, in Pima Indians (17). Furthermore, 
rs1885088 was associated with T2DM in a dominant model; 
however, this association did not remain significant following a 
genome-wide association study using the summary association 
statistics from the Diabetes Genetics Initiative and Wellcome 
Trust Case-Control Consortium studies. Differences in the 
clinical characteristics of the case-control populations and 
ancestral genetic background may have accounted for these 
results (18).
Notably, sulfonylurea sensitivity has been described as 
a feature of HNF1A- and HNF4A-associated maturity-onset 
diabetes in the young (19). The sulfonyl-urea receptor-1 
subunit of the pancreatic β-cell ATP-sensitive potassium 
(KATP) channel is encoded by the ABCC8 gene, which is 
located 4,200 bp upstream of the KCNJ11 gene. These findings 
suggested that the functions of HNF4A and HNF1A in T2DM 
may be associated with obesity and lipid metabolism. In the 
present study, 77% of participants had a BMI of ≥25 kg/m2, 
Figure 2. Effects of KCNJ11, HNF4A and TCF7L2 genotypes on quantitative traits. (A) KCNJ11 rs5210 SNP for (a) HbA1c and (b) OGTT120. (B) HNF4A 
rs1885088 SNP LDL levels. (C) TCF7L2 rs11196175 SNP on (a) cholesterol, (b) LDL and (c) BMI. (D) TCF7L2 rs12255372 SNP on (a) BMI, (b) triglycerides, 
(c) VLDL, (d) LDL and (e) HDL. SNP, single nucleotide polymorphisms; LDL, low-density lipoprotein; BMI, body mass index; VLDL, very low density 
lipoprotein; HDL, high-density lipoprotein.
  A   B
  C
  D
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and 54.3% suffered from T2DM (Table I). In addition, it was 
demonstrated that the HNF4A locus was directly correlated 
with LDL levels, but not with T2DM.
In the Northeastern Mexican population analyzed in the 
present study, the KCNJ11 rs5210 SNP [minor allele frequency 
(MAF)=0.373] was associated with T2DM; however, the 
KCNJ11 SNPs that have previously been associated with 
T2DM in European populations (rs5218 and rs5219), were not 
associated with T2DM in the present study. In the presently 
analyzed population, rs5218 had a MAF of 0.209 and rs5219 
had a MAF of 0.329. Similarly, two previous studies analyzing 
the Mestizo population of Mexico City were unable to iden-
tify an association between rs5219 and T2DM (20,21). In 
particular, the frequency of the risk allele was shown to be too 
low to reach the power in order to detect an association (20). 
Furthermore, a previous study analyzed 9.2 million SNPs in 
Mexican (n=8,214; Mexico City) and Latin American (n=3,848) 
patients with T2DM and in 4,366 non-diabetic control (22). 
These studies detected an association between T2DM and 
TCF7L2, KCNQ1 and SLC16A11 loci, but did not identify an 
association between T2DM and rs5219 (genome‑wide signifi-
cance, P<1x10-8). A systematic meta-analysis of the effect of 
the KCNJ11 rs5219 SNP (23) in 48 published studies (T2DM 
cases, 56,349; controls, 81,800; family trios, 483) reported that 
rs5216 was significantly associated with an increased risk of 
T2DM (P<10-5) when using the heterozygous and homozy-
gous model (20). The low frequency of KCNJ11 risk alleles 
in case-control studies may explain the inability to associate 
them with T2DM.
TCF7L2 (24), HNF4A (25) and KCNJ11 (26,27) have been 
associated with sulfonylurea sensitivity in previous studies, 
and the present study demonstrated an association with levels 
of LDL (HNF4A) and T2DM (KCNJ11).
The TCF7L2 gene has previously been associated with 
T2DM, insulin sensitivity and resistance (28). In addition, the 
rs7903146 SNP has been reported to be a risk factor of non-alco-
holic fatty liver disease and of various metabolic disorders 
involving glucose and lipoprotein homeostasis (29,30). In the 
Northeastern Mexican population, the CC and CT genotypes 
of the rs11196175 (TCF7L2) SNP were associated with a lower 
BMI and elevated levels of cholesterol and LDL, as compared 
with the TT genotype. The rs11196175 SNP has previously been 
associated with a variety of diseases/phenomena, including 
cancer (31) and metabolic syndrome in women with polycystic 
ovary syndrome (European Caucasian ancestry); however, 
this finding did not remain statistically significant following 
correction for multiple testing, and this was likely due to 
sample size (32), smoking (33) and adaptation to climate (34).
In the present study, the TCF7L2 rs12255372 GG genotype 
was associated with a higher BMI and HDL levels, and lower 
levels of VLDL and LDL, as compared with the GT genotype. 
However, the TCF7L2 rs12255372 SNP has been extensively 
studied and has previously been associated with T2DM (35) 
in numerous populations, including Iranian (36), Indian (37), 
Japanese (38), Chinese (39) and South Asian (40) populations, 
whereas it has been associated with BMI in Pima Indians (41) 
and the Mexico City population (with ADMIXMAP adjust-
ment) (42). Furthermore, this SNP has been associated with the 
expression of proinsulin in pancreatic islets when applying the 
additive genetic model (43). In addition, it has been associated 
with gestational diabetes mellitus and it was shown, in additive 
and dominant models, to interact with adiposity to alter insulin 
secretion in Mexican Americans (44). Applying the same 
genetic model, the present study demonstrated an association 
with dyslipidemia, although not with T2DM. These results 
suggested that ethnic background, lipid metabolism, obesity 
and T2DM may be interlinked; however, the consensus is an 
T2DM association (39).
It has previously been reported that the Mexican popula-
tion is genetically diverse (6); therefore, a more detailed study 
of population structure alongside geographical data is required 
in order to assess the frequency and the prevalence of genetic 
diseases in native and Mestizo Mexican populations (6). The 
Mexican population is an interesting model for genetic studies 
due to the great ethnic diversity within native and Mestizo 
populations. A previous study reported significant differ-
ences according to geographic region in Mexico (6), and this 
significant genetic variation highlights the need for a thorough 
analysis of Mexican populations. Once this information is 
collected, it may be used as a reference for Mexican genetic 
studies. 
In conclusion, the present study identified SNPs associ-
ated with T2DM, BMI and dyslipidemia, in 39 families from 
Figure 4. Linkage disequilibrium and block structure for the TCF7L2 single 
nucleotide polymorphisms rs10885390, rs11196175, rs7903146, rs10885406, 
rs12255372 and rs290487.
Figure 3. Linkage disequilibrium and block structure for the KCNJ11 single 
nucleotide polymorphisms rs5210, rs5218, and rs5219.
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Northeastern Mexico. In particular, FBAT analyses (without 
population stratification) identified an association between 
the KCNJ11, TCF7L2 and HNF4A genes and T2DM, dyslip-
idemia and obesity. These associations between HNF4A and 
TCF7L2 and lipid homeostasis and obesity, and between 
KCNJ11 and T2DM, form a complex model in which insulin 
resistance/sensitivity is a common factor. Due to the signifi-
cant genetic diversity of the Mexican population, case-control 
studies enrolling >2,000 subjects are required in order to 
confirm the associations identified in the present study.
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